Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yesim Ozguler

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Rheumatology (Oxford, England)|January 8, 2026
Efficacy and tolerability of switching from coated to compressed colchicine preparations in patients with Behçet syndromeSena Fidan, Sinem Nihal Esatoglu, Yesim Ozguler, et al.
Annals of the Rheumatic Diseases|August 3, 2022
Behçet's disease risk-variant HLA-B51/ERAP1-Hap10 alters human CD8 T cell immunityAnn Cavers, Matthias Christian Kugler, Yesim Ozguler, et al.
Annals of Neurology|July 28, 2017
Myelopathy in Behçet's disease: The Bagel SignUgur Uygunoglu, Burcu Zeydan, Yesim Ozguler, et al.
Journal of Neurology|July 8, 2025
Central nervous system involvement and mimickers in ANCA associated vasculitisYeliz Yagiz Ozogul, Sinem Nihal Esatoglu, Murat Ozogul, et al.
Rheumatology (Oxford, England)|June 3, 2022
Frequency of AA amyloidosis has decreased in Behçet's syndrome: a retrospective study with long-term follow-up and a systematic reviewGuzin Karatemiz, Sinem Nihal Esatoglu, Mert Gurcan, et al.
Frontiers in Immunology|January 8, 2021
Immunogenicity of Infliximab Among Patients With Behçet Syndrome: A Controlled StudySinem Nihal Esatoglu, Fatma Nihan Akkoc-Mustafayev, Yesim Ozguler, et al.
Rheumatology International|November 26, 2021
The incidence, clinical characteristics, and outcome of COVID-19 in a prospectively followed cohort of patients with Behçet's syndromeGuzin Ozcifci, Tahacan Aydin, Zeynep Atli, et al.
The Journal of Rheumatology|September 17, 2015
Current Status, Goals, and Research Agenda for Outcome Measures Development in Behçet Syndrome: Report from OMERACT 2014Gulen Hatemi, Yesim Ozguler, Haner Direskeneli, et al.
Clinical Immunology (Orlando, Fla.)|June 29, 2023
Infliximab for vascular involvement in Behçet's syndromeGulen Hatemi, Nur Beyza Tukek, Sinem Nihal Esatoglu, et al.
Seminars in Arthritis and Rheumatism|February 10, 2025
Venous ulcers in Behçet syndromeAlican Karakoc, Yesim Ozguler, Ayse Ozdede, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Rheumatology (Oxford, England)|January 8, 2026
Efficacy and tolerability of switching from coated to compressed colchicine preparations in patients with Behçet syndromeSena Fidan, Sinem Nihal Esatoglu, Yesim Ozguler, et al.
Annals of the Rheumatic Diseases|August 3, 2022
Behçet's disease risk-variant HLA-B51/ERAP1-Hap10 alters human CD8 T cell immunityAnn Cavers, Matthias Christian Kugler, Yesim Ozguler, et al.
Annals of Neurology|July 28, 2017
Myelopathy in Behçet's disease: The Bagel SignUgur Uygunoglu, Burcu Zeydan, Yesim Ozguler, et al.
Journal of Neurology|July 8, 2025
Central nervous system involvement and mimickers in ANCA associated vasculitisYeliz Yagiz Ozogul, Sinem Nihal Esatoglu, Murat Ozogul, et al.
Rheumatology (Oxford, England)|June 3, 2022
Frequency of AA amyloidosis has decreased in Behçet's syndrome: a retrospective study with long-term follow-up and a systematic reviewGuzin Karatemiz, Sinem Nihal Esatoglu, Mert Gurcan, et al.
Frontiers in Immunology|January 8, 2021
Immunogenicity of Infliximab Among Patients With Behçet Syndrome: A Controlled StudySinem Nihal Esatoglu, Fatma Nihan Akkoc-Mustafayev, Yesim Ozguler, et al.
Rheumatology International|November 26, 2021
The incidence, clinical characteristics, and outcome of COVID-19 in a prospectively followed cohort of patients with Behçet's syndromeGuzin Ozcifci, Tahacan Aydin, Zeynep Atli, et al.
The Journal of Rheumatology|September 17, 2015
Current Status, Goals, and Research Agenda for Outcome Measures Development in Behçet Syndrome: Report from OMERACT 2014Gulen Hatemi, Yesim Ozguler, Haner Direskeneli, et al.
Clinical Immunology (Orlando, Fla.)|June 29, 2023
Infliximab for vascular involvement in Behçet's syndromeGulen Hatemi, Nur Beyza Tukek, Sinem Nihal Esatoglu, et al.
Seminars in Arthritis and Rheumatism|February 10, 2025
Venous ulcers in Behçet syndromeAlican Karakoc, Yesim Ozguler, Ayse Ozdede, et al.
Pageof 6